Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced a multi-year partnership with Illumina, Inc. (NASDAQ: ILMN), to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for…